Anticoagulation management associated with extracorporeal circulation

Best Practice and Research: Clinical Anaesthesiology

Volumn 29, Issue 2, 2015, Pages 189-202

  Sniecinski, Roman M ^a   Levy, Jerrold H ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

antithrombin III; cardiopulmonary bypass; heparin resistance; unfractionated heparin; whole blood activated coagulation time

Indexed keywords

ARGATROBAN; BLOOD CLOTTING FACTOR; DANAPAROID; ECARIN; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; THROMBIN INHIBITOR; ANTICOAGULANT AGENT;

ACTIVATED CLOTTING TIME; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BIOLOGICAL MONITORING; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CLINICAL EVALUATION; CONCENTRATION RESPONSE; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG MONITORING; EXTRACORPOREAL CIRCULATION; EXTRACORPOREAL OXYGENATION; HEART SURGERY; HUMAN; MANAGED CARE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBUS; TREATMENT RESPONSE; URINARY EXCRETION; ADVERSE EFFECTS; ANIMAL; DISEASE MANAGEMENT; DRUG EFFECTS; HEMOSTASIS; PHYSIOLOGY;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; DISEASE MANAGEMENT; EXTRACORPOREAL CIRCULATION; HEMOSTASIS; HEPARIN; HUMANS;

EID: 84947028576     PISSN: 15216896     EISSN: 1532169X     Source Type: Journal    
DOI: 10.1016/j.bpa.2015.03.005     Document Type: Review

References (77)

1. E.A. Hessel 2nd A brief history of cardiopulmonary bypass Semin Cardiothorac Vasc Anesth 18 2014 87 100
2. M.W. Lim The history of extracorporeal oxygenators Anaesthesia 61 2006 984 995
3. D. Wardrop, and D. Keeling The story of the discovery of heparin and warfarin Br J Haematol 141 2008 757 763
4. R.T. Patrick, R.A. Theye, and E.A. Moffitt Studies in extracorporeal circulation. V. Anesthesia and supportive care during intracardiac surgery with the Gibbon-type pump-oxygenator Anesthesiology 18 1957 673 685
5. P.G. Hattersley Activated coagulation time of whole blood JAMA 196 1966 436 440
6. B.S. Bull, R.A. Korpman, W.M. Huse, and et al. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols J Thorac Cardiovasc Surg 69 1975 674 684
7. R.M. Sniecinski, and W.L. Chandler Activation of the hemostatic system during cardiopulmonary bypass Anesth Analg 113 2011 1319 1333
8. R.J. Linhardt, and N.S. Gunay Production and chemical processing of low molecular weight heparins Semin Thromb Hemost 25 Suppl. 3 1999 5 16
9. J. Hirsh, S.S. Anand, J.L. Halperin, and et al. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association Circulation 103 2001 2994 3018
10. J.I. Weitz, M. Hudoba, D. Massel, and et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors J Clin Investig 86 1990 385 391
11. D.M. Tollefsen, D.W. Majerus, and M.K. Blank Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma J Biol Chem 257 1982 2162 2169
12. T.K. Giri, and D.M. Tollefsen Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II Blood 107 2006 2753 2758
13. K.A. Tanaka, F. Szlam, J. Vinten-Johansen, and et al. Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan Thromb Haemost 94 2005 808 813
14. J.B. Hansen, B. Svensson, R. Olsen, and et al. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro Thromb Haemost 83 2000 937 943
15. C.A. de Swart, B. Nijmeyer, J.M. Roelofs, and et al. Kinetics of intravenously administered heparin in normal humans Blood 60 1982 1251 1258
16. H.R. Lijnen, M. Hoylaerts, and D. Collen Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma J Biol Chem 258 1983 3803 3808
17. C.A. de Swart, B. Nijmeyer, L.O. Andersson, and et al. Elimination of high affinity heparin fractions and their anticoagulant and lipase activity Blood 63 1984 836 842
18. G.P. Gravlee, K.C. Angert, W.Y. Tucker, and et al. Early anticoagulation peak and rapid distribution after intravenous heparin Anesthesiology 68 1988 126 129
19. B. Boneu, C. Caranobe, and P. Sie Pharmacokinetics of heparin and low molecular weight heparin Bailliere's Clin Haematol 3 1990 531 544
20. T.E. Warkentin, and A. Greinacher Heparin-induced thrombocytopenia and cardiac surgery Ann Thorac Surg 76 2003 638 648
21. J.H. Levy, and A.M. Winkler Heparin-induced thrombocytopenia and cardiac surgery Curr Opin Anaesthesiol 23 2010 74 79
22. C. Gao, B. Boylan, J. Fang, and et al. Heparin promotes platelet responsiveness by potentiating alphaIIbbeta3-mediated outside-in signaling Blood 117 2011 4946 4952
23. Z. Xiao, and P. Theroux Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor Circulation 97 1998 251 256
24. E. Gray, B. Mulloy, and T.W. Barrowcliffe Heparin and low-molecular-weight heparin Thromb Haemost 99 2008 807 818
25. S. Massonnet-Castel, E. Pelissier, L. Bara, and et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation Haemostasis 16 1986 139 146
26. M.J. Wilhelm, C. Schmid, D. Kececioglu, and et al. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172 Ann Thorac Surg 61 1996 920 924
27. H.N. Magnani, and A. Gallus Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004 Thromb Haemost 95 2006 967 981
28. D. Hoppensteadt, J.M. Walenga, J. Fareed, and et al. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation Hematology/Oncol Clin N Am 17 2003 313 341
29. T.E. Warkentin, R.J. Cook, V.J. Marder, and et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin Blood 106 2005 3791 3796
30. A.I. Parlar, U. Sayar, D. Cevirme, and et al. Successful use of fondaparinux in a patient with heparin-induced thrombocytopenia while on extracorporeal membrane oxygenation after mitral valve redo surgery Int J Artif Organs 37 2014 344 347
31. A.M. Winkler, and C.A. Tormey Pathology consultation on monitoring direct thrombin inhibitors and overcoming their effects in bleeding patients Am J Clin Pathol 140 2013 610 622
32. R.C. Becker Hirudin-based anticoagulant strategies for patients with suspected heparin-induced thrombocytopenia undergoing percutaneous coronary interventions and bypass grafting J Thromb Thrombolysis 10 Suppl. 1 2000 59 68
33. M.L. Willey, S. de Denus, and S.A. Spinler Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis Pharmacotherapy 22 2002 492 499
34. D.A. Van De Car, S.V. Rao, and E.M. Ohman Bivalirudin: a review of the pharmacology and clinical application Expert Rev Cardiovasc Ther 8 2010 1673 1681
35. C.M. Dyke, N.G. Smedira, A. Koster, and et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study J Thorac Cardiovasc Surg 131 2006 533 539
36. A. Koster, C.M. Dyke, G. Aldea, and et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial Ann Thorac Surg 83 2007 572 577
37. C.H. Dang, V.L. Durkalski, and J.M. Nappi Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia Pharmacotherapy 26 2006 461 468
38. M.E. Martin, G.H. Kloecker, and D.A. Laber Argatroban for anticoagulation during cardiac surgery Eur J Haematol 78 2007 161 166
39. F. Follis, G. Filippone, G. Montalbano, and et al. Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative? Interact Cardiovasc Thorac Surg 10 2010 592 596
40. T.E. Warkentin, A. Greinacher, A. Koster, and et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) Chest 133 2008 340S 380S
41. S.A. Spinler, A.K. Wittkowsky, E.A. Nutescu, and et al. Anticoagulation monitoring part 2: unfractionated heparin and low-molecular-weight heparin Ann Pharmacother 39 2005 1275 1285
42. G.J. Despotis, A.L. Summerfield, J.H. Joist, and et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations J Thorac Cardiovasc Surg 108 1994 1076 1082
43. A. Koster, G. Despotis, M. Gruendel, and et al. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation Anesth Analg 95 2002 26 30 table of contents
44. J.S. Wang, C.Y. Lin, and R.B. Karp Comparison of high-dose thrombin time with activated clotting time for monitoring of anticoagulant effects of heparin in cardiac surgical patients Anesth Analg 79 1994 9 13
45. I.P. Casserly, D.J. Kereiakes, W.A. Gray, and et al. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration Thromb Res 113 2004 115 121
46. A. Koster, S. Buz, T. Krabatsch, and et al. Monitoring of bivalirudin anticoagulation during and after cardiopulmonary bypass using an ecarin-activated TEG system J Cardiac Surg 23 2008 321 323
47. E. Schaden, A. Schober, S. Hacker, and et al. Ecarin modified rotational thromboelastometry: a point-of-care applicable alternative to monitor the direct thrombin inhibitor argatroban Wien Klin 125 2013 156 159
48. G.J. Despotis, J.H. Joist, L.T. Goodnough, and et al. Whole blood heparin concentration measurements by automated protamine titration agree with plasma anti-Xa measurements J Thorac Cardiovasc Surg 113 1997 611 613
49. S. Garvin, D.C. FitzGerald, G. Despotis, and et al. Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements Anesth Analg 111 2010 849 855
50. G.D. Wool, and C.M. Lu Pathology consultation on anticoagulation monitoring: factor X-related assays Am J Clin Pathol 140 2013 623 634
51. J.A. Young, C.T. Kisker, and D.B. Doty Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer Ann Thorac Surg 26 1978 231 240
52. J.S. Wang, C.Y. Lin, W.T. Hung, and et al. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin Anesthesiology 77 1992 1080 1084
53. M.A. Smythe, E.A. Nutescu, and A.K. Wittkowsky Changes in the USP heparin monograph and implications for clinicians Pharmacotherapy 30 2010 428 431
54. D.A. Anderson, and D.W. Holt Has the new USP assay for heparin affected dosage for patients undergoing cardiopulmonary bypass? J Extra-Corpor Technol 45 2013 112 115
55. R.L. Lobato, G.J. Despotis, J.H. Levy, and et al. Anticoagulation management during cardiopulmonary bypass: a survey of 54 North American institutions J Thorac Cardiovasc Surg 139 2010 1665 1666
56. B.S. Bull, W.M. Huse, F.S. Brauer, and et al. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage J Thorac Cardiovasc Surg 69 1975 685 689
57. M. Ranucci, A. Balduini, A. Ditta, and et al. A systematic review of biocompatible cardiopulmonary bypass circuits and clinical outcome Ann Thorac Surg 87 2009 1311 1319
58. A. Finley, and C. Greenberg Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass Anesth Analg 116 2013 1210 1222
59. M.H. Staples, R.F. Dunton, K.J. Karlson, and et al. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping Ann Thorac Surg 57 1994 1211 1216
60. M.R. Williams, A.B. D'Ambra, J.R. Beck, and et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance Ann Thorac Surg 70 2000 873 877
61. B.D. Spiess Treating heparin resistance with antithrombin or fresh frozen plasma Ann Thorac Surg 85 2008 2153 2160
62. L.C. John, G.M. Rees, and I.B. Kovacs Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage J Thorac Cardiovasc Surg 105 1993 816 822
63. K.H. Teoh, E. Young, C.A. Bradley, and et al. Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass Circulation 88 1993 II420 II425
64. M. Ranucci, G. Isgro, A. Cazzaniga, and et al. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting Perfusion 14 1999 437 442
65. J. Bharadwaj, C. Jayaraman, and R. Shrivastava Heparin resistance Lab Hematol Off Publ Int Soc Lab Hematol 9 2003 125 131
66. T. Chan, N.C. Hwang, and C.H. Lim A statistical analysis of factors predisposing patients to heparin resistance Perfusion 21 2006 99 103
67. S. Garvin, D. Fitzgerald, J.D. Muehlschlegel, and et al. Heparin dose response is independent of preoperative antithrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations Anesth Analg 111 2010 856 861
68. J.H. Lemmer Jr., and G.J. Despotis Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery J Thorac Cardiovasc Surg 123 2002 213 217
69. M.S. Avidan, J.H. Levy, H. van Aken, and et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass J Thorac Cardiovasc Surg 130 2005 107 113
70. A.H. Sabbagh, G.K. Chung, P. Shuttleworth, and et al. Fresh frozen plasma: a solution to heparin resistance during cardiopulmonary bypass Ann Thorac Surg 37 1984 466 468
71. A. Koster, T. Fischer, M. Gruendel, and et al. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation J Cardiothorac Vasc Anesth 17 2003 171 175
72. M. Kikura, K. Tanaka, and T. Hiraiwa Nafamostatmesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass J Cardiothorac Vasc Anesth 26 2012 239 244
73. V.A. Ferraris, J.R. Brown, G.J. Despotis, and et al. 2011 Update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines Ann Thorac Surg 91 2011 944 982
74. G.J. Despotis, J.H. Joist, C.W. Hogue Jr., and et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation J Thorac Cardiovasc Surg 110 1995 46 54
75. A. Koster, T. Fischer, M. Praus, and et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management Anesthesiology 97 2002 837 841
76. E. Ovrum, E.A. Holen, G. Tangen, and et al. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects Ann Thorac Surg 60 1995 365 371
77. R.D. Slight, R. Buell, O.C. Nzewi, and et al. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass J Cardiothorac Vasc Anesth 22 2008 47 52